Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRAYNASDAQ:PRPHNASDAQ:SESNNASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRAYGraybug Vision$2.00-2.9%$1.83$5.00▼$22.12$3.14M1.22,165 shs13,748 shsPRPHProPhase Labs$0.33+7.9%$0.35$0.22▼$5.45$13.69M-0.472.66 million shs587,952 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsSTTKShattuck Labs$0.99+4.4%$1.00$0.69▼$11.76$47.42M1.74373,621 shs40,772 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRAYGraybug Vision0.00%+14.29%+35.14%-27.27%-64.29%PRPHProPhase Labs+7.92%+11.00%+6.00%+24.71%-93.52%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%STTKShattuck Labs+4.44%-0.89%+4.22%-16.81%-90.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs1.2709 of 5 stars0.02.00.00.03.81.71.3SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ASTTKShattuck Labs2.3224 of 5 stars3.42.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRAYGraybug Vision 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/ASESNSesen Bio 0.00N/AN/AN/ASTTKShattuck Labs 2.71Moderate Buy$7.50657.58% UpsideCurrent Analyst Ratings BreakdownLatest SESN, STTK, GRAY, and PRPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/17/2025STTKShattuck LabsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$4.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/APRPHProPhase Labs$6.77M2.02N/AN/A$2.74 per share0.12SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00STTKShattuck Labs$4.61M10.30N/AN/A$3.41 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/APRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ASTTKShattuck Labs-$87.30M-$1.39N/AN/AN/A-1,156.46%-61.92%-54.49%N/ALatest SESN, STTK, GRAY, and PRPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025STTKShattuck Labs-$0.29-$0.27+$0.02-$0.27N/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRAYGraybug VisionN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRAYGraybug VisionN/A10.7310.72PRPHProPhase Labs0.481.471.33SESNSesen BioN/A6.106.10STTKShattuck LabsN/A7.967.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRAYGraybug Vision49.94%PRPHProPhase Labs9.45%SESNSesen Bio16.45%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipGRAYGraybug Vision7.94%PRPHProPhase Labs20.70%SESNSesen Bio3.20%STTKShattuck Labs10.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableSTTKShattuck Labs10047.90 million42.73 millionOptionableSESN, STTK, GRAY, and PRPH HeadlinesRecent News About These CompaniesShattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 11 at 2:53 AM | americanbankingnews.comShattuck Labs Advances SL-325 Program Amid Financial ProgressMay 6, 2025 | tipranks.com683 Capital Management LLC Buys New Position in Shattuck Labs, Inc. (NASDAQ:STTK)May 4, 2025 | marketbeat.comShattuck Labs Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 1, 2025 | globenewswire.comShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comShattuck Labs Full Year 2024 Earnings: Misses ExpectationsMarch 29, 2025 | uk.finance.yahoo.comShattuck Labs reports Q4 EPS (37c), consensus (32c)March 29, 2025 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)March 29, 2025 | markets.businessinsider.comShattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | finanznachrichten.deShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationMarch 18, 2025 | msn.comShattuck Labs initiated with an Outperform at LeerinkMarch 17, 2025 | markets.businessinsider.comFavourable Signals For Shattuck Labs: Numerous Insiders Acquired StockMarch 11, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)February 21, 2025 | markets.businessinsider.comShattuck Labs’ SL-325 shows positive results in inflammatory bowel diseaseFebruary 20, 2025 | markets.businessinsider.comShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 20, 2025 | globenewswire.comShattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in BerlinFebruary 13, 2025 | quiverquant.comShattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 13, 2025 | globenewswire.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | markets.businessinsider.comShattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | quiverquant.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis CongressFebruary 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSESN, STTK, GRAY, and PRPH Company DescriptionsGraybug Vision NASDAQ:GRAY$2.00 -0.06 (-2.91%) As of 05/9/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.ProPhase Labs NASDAQ:PRPH$0.33 +0.02 (+7.92%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.31 -0.01 (-3.98%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Shattuck Labs NASDAQ:STTK$0.99 +0.04 (+4.44%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.01%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
